Japan bladder cancer market is estimated to grow modestly at a CAGR of around 10.2% during the forecast period. Due to the well-established healthcare industry and awareness about bladder cancer and its treatment, the opportunities for drugs and devices for bladder cancer exist substantially in Japan. The mortality caused due to cancer in Japan is estimated to around 0.37 million in 2017. According to the Tsugane’s contribution to cancer research, the Population Attributable Fraction (PAF) of tobacco smoking to cancer was 24%, alcohol drinking was 6%, and over-intake of salt was 1.4%. The causes of the other 50% of cancer death were not sufficiently clarified.

A full Report of Japan Bladder Cancer Market at https://www.omrglobal.com/industry-reports/japan-bladder-cancer-market

Japan bladder cancer market is segmented into cancer type, diagnosis, and treatment. Based on cancer type, the market is segmented into transitional cell bladder cancer/ urothelial carcinoma, squamous cell bladder cancer, adenocarcinoma, and other rare types (sarcomas, carcinoma in situ). Based on the diagnosis, the market is segmented into cystoscopy, biopsy, urinalysis, urine cytology, intravenous pyelogram (IVP), and others. Based on treatment, the market is segmented into chemotherapy, immunotherapy, radiation therapy, surgery, and other treatment which include targeted therapy. The cystoscopy procedure is the most used method in the diagnosis and treatment of bladder cancer. The cystoscopy uses special tools that may be passed through cystoscope to treat exceedingly small bladder tumors, which might be removed during cystoscopy. Therefore, it is highly adopted for the diagnosis of the disease.

To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/japan-bladder-cancer-market

Some key players mentioned in the research report are:

The companies which are contributing to the growth of the Japan bladder cancer market include AstraZeneca PLC, Bristol-Myers Squibb, Co., Eli Lilly & Co., GlaxoSmithKline PLC, Sysmex Corp., and Pfizer, Inc. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, funding to the start-ups, and technological advancements to stay competitive in the market.

Japan Bladder Cancer Market Segmentation

By Cancer Type

• Transitional Cell Bladder Cancer/ Urothelial Carcinoma
• Squamous Cell Bladder Cancer
• Adenocarcinoma
• Others (Sarcomas, Carcinoma in Situ)

By Diagnosis

• Cystoscopy
• Biopsy
• Urinalysis
• Urine Cytology
• Intravenous Pyelogram (IVP)
• Others (Biomarkers)

By Treatment

• Surgery
• Chemotherapy
• Immunotherapy
• Radiation Therapy
• Others (Targeted Therapy)
:
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/japan-bladder-cancer-market

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

For More Information, Visit https://www.omrglobal.com

Media Contact:

Company Name: Orion Market Research
Contact Person: Mr. AnuragTiwari
Email: [email protected]
Contact no: +1 646-755-7667, +91 780-304-0404